Vaxcyte, Inc.2023财年实现净利润-4.02亿美元，同比减少80.27%

自选股智能写手03-03

12月31日，Vaxcyte, Inc.（PCVX.US）公布财报，公告显示公司2023财年净利润为-4.02亿美元，同比减少80.27%；其中营业收入为0.00美元，每股基本收益为-4.14美元。从资产负债表来看，Vaxcyte, Inc.（PCVX.US）总负债1.67亿美元，其中短期债务7.11百万美元，资产负债比为8.44，流动比率为7.56。机构评级：截至2023年12月31日，当前有7...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2416964119?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-03 00:24","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2416964119","market":"us","top_or_hot":-1,"title":"Vaxcyte, Inc.2023财年实现净利润-4.02亿美元，同比减少80.27%","media":"自选股智能写手","content":"<div>\n<p>12月31日，Vaxcyte, Inc.（PCVX.US）公布财报，公告显示公司2023财年净利润为-4.02亿美元，同比减少80.27%；其中营业收入为0.00美元，每股基本收益为-4.14美元。从资产负债表来看，Vaxcyte, Inc.（PCVX.US）总负债1.67亿美元，其中短期债务7.11百万美元，资产负债比为8.44，流动比率为7.56。机构评级：截至2023年12月31日，当前有7...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403030024108afa651c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxcyte, Inc.2023财年实现净利润-4.02亿美元，同比减少80.27%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxcyte, Inc.2023财年实现净利润-4.02亿美元，同比减少80.27%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-03 00:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403030024108afa651c&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月31日，Vaxcyte, Inc.（PCVX.US）公布财报，公告显示公司2023财年净利润为-4.02亿美元，同比减少80.27%；其中营业收入为0.00美元，每股基本收益为-4.14美元。从资产负债表来看，Vaxcyte, Inc.（PCVX.US）总负债1.67亿美元，其中短期债务7.11百万美元，资产负债比为8.44，流动比率为7.56。机构评级：截至2023年12月31日，当前有7...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403030024108afa651c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PCVX","symbol_name":"Vaxcyte, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403030024108afa651c&s=b","article_id":"2416964119","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403030024108afa651c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2416964119","pubTimestamp":1709396647,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"12月31日，Vaxcyte, Inc.公布财报，公告显示公司2023财年净利润为-4.02亿美元，同比减少80.27%；其中营业收入为0.00美元，每股基本收益为-4.14美元。从资产负债表来看，Vaxcyte, Inc.总负债1.67亿美元，其中短期债务7.11百万美元，资产负债比为8.44，流动比率为7.56。机构评级：截至2023年12月31日，当前有7家机构对Vaxcyte, Inc.目标价做出预测，其中目标均价为97.00美元，其中最低目标价为69.00美元，最高目标价为108.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"PCVX":"Vaxcyte, Inc."},"translate_title":"Vaxcyte, Inc. achieved a net profit of-402 million US dollars in fiscal year 2023, a year-on-year decrease of 80.27%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCVX":1},"content_text":"12月31日，Vaxcyte, Inc.（PCVX.US）公布财报，公告显示公司2023财年净利润为-4.02亿美元，同比减少80.27%；其中营业收入为0.00美元，每股基本收益为-4.14美元。从资产负债表来看，Vaxcyte, Inc.（PCVX.US）总负债1.67亿美元，其中短期债务7.11百万美元，资产负债比为8.44，流动比率为7.56。机构评级：截至2023年12月31日，当前有7家机构对Vaxcyte, Inc.目标价做出预测，其中目标均价为97.00美元，其中最低目标价为69.00美元，最高目标价为108.00美元。公司简介：Vaxcyte Inc是一家疫苗公司，致力于通过开发新型疫苗来治疗最常见和致命疾病的患者来改善全球健康。其产品包括肺炎球菌结合疫苗。该公司的候选产品包括VAX-24、VAX-XP、VAX-A1和VAX-PG。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2416964119"}